Actinium
Pharmaceuticals, a biopharmaceutical company with a proprietary platform that
combines the precision targeting of monoclonal antibodies with the killing
power of alpha and beta radioisotopes, today reported the voting results from
its annual general meeting of shareholders (the “meeting”) which was held last
Monday.
Holders
of approximately 80 percent, or 18.3 million, of Actinium Pharmaceuticals’
outstanding shares as of the record date November 7, 2013, participated in the
voting at the meeting. According to today’s press release, all of the proposed
resolutions were approved and ratified including Proposal 1 which showed
unanimous support for the Board of Directors.
Commenting
on the results of the meeting, Mr. Sandesh Seth, Chairman of the Board of
Actinium Pharmaceuticals, stated, “We are thankful that our shareholders took
the time to show their support for the Company and its Board of Directors by
voting in such large numbers. We will strive to meet their expectations as we
steer the Company from a strategic perspective and work with Management to
assure implementation of these strategies as Actinium progresses its lead drug
candidates Iomab™-B and Actimab-A in their planned Phase 3 and ongoing Phase
1/2 trials, respectively.”
Dr.
Kaushik J. Dave, President and CEO of Actinium Pharmaceuticals, added, “We are
pleased that so many of our shareholders were able to participate in the
Company’s annual general meeting by casting their votes on these important
proposals. We express our thanks to them in supporting further efforts by
Actinium’s Board of Directors and its Management to continue implementing our
given strategies to move the Company forward for the benefit of all
stockholders.”
For
more information on Actinium Pharmaceuticals, visit www.actiniumpharmaceuticals.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
